This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: Rexahn, Vertex, Peregrine, Sarepta

BOSTON ( TheStreet) -- Here's the last Biotech Stock Mailbag of the summer.

BuggyFunBunny writes: "A couple for the Mailbag, should you feel like it. 1) It seems that ATM/stealth financing/dilution is more common recently than in the past. What meaning should we assess? 2) Just saw that a past whipping boy has announced 'good' data: Rexahn Pharmaceuticals (RNN). What meaning should we assess this?"

U.S. companies raised $2.3 billion via 140 At-The-Market (ATM) offerings in the first quarter of the year -- a record amount and a 6% increase over the first quarter 2011, according to statistics gathered by Brinson Patrick, a boutique investment bank that specializes in facilitating ATM transactions.

ATM financing arrangements allow companies, through a broker or investment bank, to sell treasury stock to investors at current market prices. Small companies like ATMs because it's a relatively easy and cheap way to raise cash -- less expensive than a traditional follow-on stock offering managed by a traditional Wall Street investment bank. Companies also have more control over how they sell stock and raise cash through an ATM because the offering can be turned "on" or "off" as market conditions change.

Small-cap and development-stage biotech companies have definitely embraced ATMs as a preferred financing vehicle. Acadia Pharmaceuticals (ACAD), Aeterna Zentaris (AEZS), Peregrine Pharmaceuticals (PPHM - Get Report), Somaxon Pharma (SOMX) and Biocryst Pharma (BCRX) are just a small sampling of recent ATM sellers.

While I generally agree that ATMs are advantageous for smallish biotech firms, the growing popularity of this financing vehicle is not necessarily a welcome trend for investors. Companies are under no obligation to disclose the sale of stock through ATMs except in customary regulatory filings at the end of each quarter or fiscal year. In many cases, this leads to stealth dilution.

The most egregious example I've come across recently was Peregrine, which diluted shareholders by 41% in the most recent fiscal year. A large majority of the 31 million (!!) shares sold by Peregrine were through an opaque ATM facility. Shareholders had no idea Peregrine was selling all this stock unless they read through SEC filings -- something every investor should do but few get around to.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
ARNA $4.22 0.00%
PPHM $1.35 0.00%
RNN $0.72 -0.03%
VRTX $126.12 -1.40%
SRPT $13.12 -0.68%

Markets

DOW 18,094.42 +56.45 0.31%
S&P 500 2,111.67 +2.75 0.13%
NASDAQ 5,053.6140 -6.6320 -0.13%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs